Summary
Signal counts
Assets tracked: 3
Watchlist assets: 3
Registry stop assets: 1
Sponsor overview
Oslo University Hospital
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT02978612 | https://clinicaltrials.gov/study/NCT01267240 | https://clinicaltrials.gov/study/NCT01197625 | https://clinicaltrials.gov/study/NCT01926639
Assets
Linked programs
- Capecitabine: Registry Stop Signal (5/5)
- Dendritic cell vaccine: Timeline Staleness Signal (3/5)
- Radiotherapy, rituximab and DC: Results Not Found Signal (2/5)